MIT spinout Kano Therapeutics innovates safer DNA tools for gene therapy

MIT
MIT
1m ago • 1 views
Kano Therapeutics produces circular single-stranded DNA to make gene therapies safer and more effective, aiming to enable broader treatment options.
MIT spinout Kano Therapeutics innovates safer DNA tools for gene therapy
A What happened
Kano Therapeutics, an MIT spinout, develops tailor-made circular single-stranded DNA molecules to overcome toxicity and delivery challenges in gene therapies. Unlike conventional double-stranded DNA, cssDNA reduces immune response and enhances stability, allowing the insertion of larger genetic sequences. Kano's technology complements gene-editing tools like CRISPR by enabling gene replacement and addition, expanding therapeutic possibilities. The company leverages fermentation for cost-effective production and collaborates with pharmaceutical firms to integrate its DNA platform into treatments for cancer and rare genetic disorders, indicating a potential shift toward safer and more versatile genetic medicines.
★

Key insights

  • 1

    DNA format impacts gene therapy safety and delivery: Kano's use of circular single-stranded DNA reduces immune toxicity compared to conventional double-stranded DNA, addressing a key barrier to broader gene therapy application.

  • 2

    Expanding gene therapy beyond editing: CssDNA enables complete gene insertion or replacement rather than just editing existing genes, potentially treating a wider array of genetic diseases.

  • 3

    Manufacturing advances enable commercial viability: Kano's fermentation-based production method lowers costs of customized cssDNA, facilitating partnerships and scalability for pharmaceutical deployment.

Takeaways

Kano Therapeutics' cssDNA platform provides a promising path to safer, more flexible gene therapies with improved manufacturability, positioning it for significant clinical and commercial impact in genetic medicine.

Topics

Science & Research Biology Medical Research Health & Medicine Healthcare Systems Pharma & Biotech

Read the full article on MIT